Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059215 · ClinicalTrials.gov registry record · Phase 2
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
A Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 905
- Enrollment target
- 2
- Study locations
NCT00059215 is a Phase 2 study of Cardiovascular Diseases and Heart Diseases that has completed, run by Eli Lilly and Company. The registered enrollment target is 905 participants, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00059215, a Phase 2 study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 905 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel (CS-747)
Study Locations (2)
Massachusetts
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Boston
British Columbia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Victoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00059215
The ClinicalTrials.gov registry entry for NCT00059215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 905 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00059215 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, British Columbia.
Frequently Asked Questions
What is clinical trial NCT00059215 about?
NCT00059215 is a clinical study titled "A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)". The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a cath...
What is the current status of trial NCT00059215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 905 participants. The study started on 2003-04. Estimated completion is 2004-01.
What conditions does trial NCT00059215 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases.
What interventions are being tested in trial NCT00059215?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (CS-747) (DRUG).
Who is sponsoring clinical trial NCT00059215?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00059215 being conducted?
This trial has 2 study locations across Massachusetts, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.